Key Highlights: CEPHEUS Trial SubQ Dara-VRd vs VRd in Transplant-Eligible or Transplant-Deferred NDMM

Opinion
Video

Panelists discuss how the CEPHEUS study comparing subcutaneous daratumumab plus VRd vs VRd alone in patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM) provides important insights into the role of quadruplet therapy in this specific population.

Recent Videos
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
Related Content